$3.38
0.196.11%
Last update: Nov 10, 4:01 PM
OnKure Therapeutics Inc
OKURNASDAQ
OnKure Therapeutics rose 0.6% from $3.17 to $3.19, behind the S&P 500's +9.8%. Its worst day was Mar 27 (−13.1%), and its low came Oct 16 at $2.10.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
OnKure Therapeutics shares rose 16.3%, while the S&P 500 rose 0.2%.
+16.3%, the year's best day · S&P 500 +0.2%
EPS of $-0.99 beat the $-1.15 estimate on $0.00 revenue.
+7.4% · S&P 500 −0.6%
Story events cover the past 12 months · Times ET
OnKure Therapeutics shares rose 14.7%, while the S&P 500 fell 1.8%.
+14.7% · S&P 500 −1.8%
EPS of $-1.11 missed the $-0.76 estimate on $0.00 revenue (est. $200,000.00).
−10.0% · S&P 500 +1.4%
OnKure Therapeutics shares rose 14.3%, while the S&P 500 rose 0.2%.
+14.3% · S&P 500 +0.2%
EPS of $-0.31 beat the $-0.62 estimate on $0.00 revenue (est. $200,000.00).
+1.5% · S&P 500 −0.2%
OnKure Therapeutics closed at its lowest level of the year, 33.8% below where the year started.
−1.4% · S&P 500 −1.1%
EPS of $-0.36 beat the $-0.39 estimate on $0.00 revenue (est. $200,000.00).
−2.5% · S&P 500 −4.4%
Where it ended: a close of $3.19 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.42, revenue est. $500,000.00).
Nothing in the past 12 months.
All OKUR dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for OKUR and SPY from Benzinga historical bars. Not investment advice.
